About Syndax
Syndax Pharmaceuticals develops and commercializes therapies specifically for cancer patients, focusing on challenging cases like hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) breast cancer. The company conducts research and clinical trials to test the safety and effectiveness of its drugs, aiming to bring them to market after receiving regulatory approval. Syndax's main product, Entinostat, is currently in clinical trials combined with Exemestane for treating HR+, HER2- breast cancer. Unlike many competitors, Syndax targets underserved patient populations and relies on strategic partnerships and capital raises to support its research and development efforts. The goal of Syndax is to advance cancer treatment by developing new therapies that address the needs of patients with difficult-to-treat cancers.